BTG Pactual Global Asset Management’s United Therapeutics UTHR Stock Holding History

BTG Pactual Global Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,300	Closed	-$400K	–	205
2015 Q2	$400K	Sell	2,300 -700	-23%	-$126K	0.03%	164
2015 Q1	$517K	Buy	+3,000	New	+$457K	0.04%	146
2014 Q4	–	Sell	-1,770	Closed	-$228K	–	229
2014 Q3	$228K	Sell	1,770 -1,730	-49%	-$178K	0.03%	196
2014 Q2	$310K	Buy	+3,500	New	+$337K	0.04%	197

Other funds holding UTHR

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BTG Pactual Global Asset Management's UTHR Position: Q3 2015 in Review

BTG Pactual Global Asset Management sold out of United Therapeutics (UTHR) in Q3 2015, closing a stake of 2,300 shares — an estimated $400K sold.

BTG Pactual Global Asset Management first reported a position in UTHR in Q2 2014 and held it in 4 quarters. The position peaked at $517K in Q1 2015. 372 funds tracked by Wall St. Rank hold UTHR as of Q3 2015.

BTG Pactual Global Asset Management reported no remaining United Therapeutics position as of Q3 2015 after selling out during the quarter.
BTG Pactual Global Asset Management sold 2,300 United Therapeutics shares in Q3 2015, an estimated $400K.
BTG Pactual Global Asset Management first reported a position in United Therapeutics in Q2 2014 and held it in 4 quarters.
BTG Pactual Global Asset Management's United Therapeutics position peaked at $517K in Q1 2015.
372 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2015.

Based on BTG Pactual Global Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.